The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 174-180

  Alimohammadian, Mohammad Hossein ^a   Khamesipour, Ali ^b   Darabi, Haiedeh ^a   Firooz, Alireza ^b   Malekzadeh, Shirin ^a   Bahonar, Ahmad ^c   Dowlati, Yahya ^b   Modabber, Farrokh ^d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

BCG; Leishmaniasis; Vaccine

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; LEISHMANIA VACCINE; AUTOCLAVED LEISHMANIA MAJOR VACCINE; INACTIVATED VACCINE; PROTOZOAL VACCINE;

ADOLESCENT; ADULT; ARTICLE; AUTOCLAVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; LEISHMANIA MAJOR; LEISHMANIASIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; VACCINATION; ANIMAL; BIOSYNTHESIS; DRUG COMBINATION; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; ANIMALS; BCG VACCINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON TYPE II; LEISHMANIA MAJOR; LEISHMANIASIS; MALE; MIDDLE AGED; PROTOZOAN VACCINES; VACCINATION; VACCINES, INACTIVATED;

EID: 0037073536     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00458-9     Document Type: Article

References (22)

1. Modabber F. First generation leishmaniasis vaccines in clinical development: moving, but what next. Curr. Opin. Anti-infective Investig. Drugs. 2:2000;35-39.
2. Dowlati Y, Ehsasi S, Shidani B, Bahar K. Stepwise safety trial of a killed Leishmania vaccine in Iran. In: Dowlati Y, Modabber F, editors. Clinics in Dermatology, vol. 14. Amsterdam: Elsevier; 1996. p. 497-502.
3. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamesipour A, Ehsasi S, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. In: Dowlati Y, Modabber F, editors. Clinics in Dermatology 1996, vol. 14. Amsterdam: Elsevier; 1996. p. 489-95.
4. Sharifi I., Fekri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R.A.et al. Randomised vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 351:1998;1540-1543.
5. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Labaf Ghassemi R.et al. A randomized, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine. 17:1999;466-472.
6. Khalil E.A.G., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B.et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. The Lancet. 356:2000;1565-1569.
7. Hashemi-Fesharaki R., Ale-Agha S., Habibi G.R., Manhouri H., Esmail-Nia K., Mohammadi A.A.et al. Production of inactivated wet rural Leishmania major. Iranian J. Med. Sci. 23(3/4):1998;74-80.
8. Alimohammadian M.H., Hakimi H., Nikseresht M.A. The preparation and evaluation of reference leishmanin from Leishmania major for use in man for diagnostic and experimental purposes. Med. J. Islamic Repub. Iran. 7:1993;23-28.
9. Sokal J.E. Measurement of delayed skin-test responses. N. Engl. J. Med. 293:1975;501-502.
10. Ajdary S., Alimohammadian M.H., Eslami M.B., Kemp K., Kharazmi A. Comparison of the immune profile of non-healing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect. Immun. 68:2000;1760-1764.
11. Mendonca S.C.F., Russell D.G., Coutinho S.G. Analysis of human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp63). Clin. Exp. Immunol. 83:1991;472-478.
12. Mendonca S.C., Coutinho S.G., Amendoeira R.R., Marzochi M.C.A., Pirmez C. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin. Exp. Immunol. 64:1986;269-276.
13. Antunes C.M.F., Mayrink W., Magalhaes P.A., Melo M.N., Dias M., Michalick S.M.et al. Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int. J. Epidemiol. 15:1986;572-580.
14. Castes M., Blackwell J., Trujillo D., Formica S., Cabrera M., Zorrilla G.et al. Immune response in healthy volunteers vaccinated with killed Leishmania promastigotes plus BCG. Part I. Skin-test reactivity, T-cell proliferation and interferon-production. Vaccine. 12:1994;1041-1051.
15. Convit J., Castellanos P.L., Ulrich M., Castes M., Rondon A., Pinard M.E.et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J. Infect. Dis. 160:1989;104-115.
16. Mayrink W., Da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Oliveira-Lima A.et al. A field trial of a vaccine against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73:1979;385-387.
17. Mayrink W., Williams P., Da Costa C.A., Magalhaes P.A., Melo M.N., Dias M.et al. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil. Ann. Trop. Med. Parsitol. 79:1985;259-269.
18. De Luca P.M., Mayrink W., Alves C.R., Countinho S.G., Oliveira M.P., Bertho A.L.et al. Evaluation of the stability and immunogenicity of autoclaved and non-autoclaved preparations of vaccine against American tegumentary leishmaniasis. Vaccine. 17:1999;1170-1185.
19. Nascimento E., Mayrink W., Da Costa C.A., Michalick M.S., Melo M.N., Barros G.C.et al. Vaccination of human against cutaneous leishmaniasis: cellular and humoral immune responses. Infect. Immun. 58:1990;2198-2203.
20. Weigle K.A., Valderrama L., Arias A.L., Santrich C., Saravia N.G. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am. J. Trop. Med. Hyg. 44:1991;260-271.
21. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:1999;4481-4488.
22. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., Katiyar J.C. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine. 19:2001;3485-3492.